Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1705139 | 1.00 | ECE1 (0.34) | ECE1CA1CA2CA7CA14 | |
| SCHEMBL8529151 | 0.81 | ECE1 (0.33) | ECE1CA1CA2CA7CA14 | |
| SCHEMBL8529461 | 0.81 | ECE1 (0.33) | ECE1CA1CA2CA7CA14 | |
| SCHEMBL8529154 | 0.81 | ECE1 (0.33) | ECE1CA1CA2CA7CA14 | |
| SCHEMBL16682790 | 0.79 | ECE1 (0.37) | ECE1 | |
| SCHEMBL1705634 | 0.79 | SLC22A6 (0.36) | CA1CA2CA7CA14 | |
| SCHEMBL26834901 | 0.79 | CA1 (0.30) | CA1CA2CA7CA14 | |
| SCHEMBL18273753 | 0.79 | ECE1 (0.37) | ECE1 | |
| SCHEMBL20363304 | 0.79 | ECE1 (0.33) | ECE1 | |
| SCHEMBL6698272 | 0.76 | ALDH1A1 (0.30) | ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041019-A1 | PROTEASE INHIBITORS | SERPINB1, PREP, DNPEP | ECE1 105/4885CA1 943/4885CA2 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.